NCT00843882 2026-03-18
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
54 trialsNCT06499285 2026-03-11
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda
Phase 3 Recruiting
NCT02048813 2025-11-28
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06018883 2025-08-07
PTCA199-3
Fudan University
Phase 3 Active not recruiting
NCT04717414 2025-07-10
INDEPENDENCE
Celgene
Phase 3 Active not recruiting
NCT05407987 2025-04-25
FORGE II
AHS Cancer Control Alberta
Phase 3 Recruiting
NCT03837171 2024-06-25
TRANSPORT
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT00310232 2024-04-02
Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)
Ontario Clinical Oncology Group (OCOG)
Phase 3 Terminated
NCT00060398 2023-06-15
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT05704894 2023-01-30
Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens
Blau Farmaceutica S.A.
Phase 3 Unknown
NCT02631070 2021-12-17
MEDALIST
Celgene
Phase 3 Completed
NCT04910594 2021-08-11
Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Unknown
NCT00303784 2020-11-27
PATCH
University College, London
Phase 3 Unknown
NCT00004917 2020-10-22
Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01773187 2020-09-29
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma
Phase 3 Terminated
NCT00070382 2020-08-03
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
Jonsson Comprehensive Cancer Center
Phase 3 Completed
NCT03776032 2018-12-20
A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy
Amgen
Phase 3 Completed
NCT00281892 2018-05-11
Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia
German CLL Study Group
Phase 3 Completed
NCT00338286 2018-03-19
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Janssen Research & Development, LLC
Phase 3 Completed
NCT00236951 2018-02-20
Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy
American Regent, Inc.
Phase 3 Completed
NCT00711958 2017-09-05
Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients
Sandoz
Phase 3 Completed
NCT00017004 2017-08-09
Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia
GOG Foundation
Phase 3 Completed
NCT02767765 2017-04-04
A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy
Hoffmann-La Roche
Phase 3 Completed
NCT01725789 2016-12-16
Ferinject® Assessment In GastRectomy Patients With Acute Isovolemic Anemia (FAIRY)
National Cancer Center, Korea
Phase 3 Completed
NCT00058331 2016-07-18
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00785356 2014-08-21
Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00482716 2014-01-10
Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT01101399 2013-12-18
FID-CHEMO
Vifor Pharma
Phase 3 Completed
NCT00003341 2013-07-03
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT00148421 2013-05-15
Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
Amgen
Phase 3 Completed
NCT00091858 2013-05-08
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
Amgen
Phase 3 Completed
NCT00118638 2013-04-29
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
Amgen
Phase 3 Completed
NCT01648946 2012-11-06
TRICCOP
Instituto do Cancer do Estado de São Paulo
Phase 3 Unknown
NCT00210587 2011-06-10
An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00210730 2011-06-10
The Duration Study
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00341055 2011-06-10
A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00261677 2011-05-23
A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy
Ortho Biotech Products, L.P.
Phase 3 Completed
NCT00246597 2011-05-19
A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer
Ortho Biotech Products, L.P.
Phase 3 Terminated
NCT00350090 2011-05-19
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
Ortho Biotech Products, L.P.
Phase 3 Terminated
NCT00270101 2011-05-18
The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00270127 2011-05-18
Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00270166 2011-05-18
The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00661999 2011-05-17
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
Mayo Clinic
Phase 3 Completed
NCT00083434 2011-04-27
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00083486 2011-04-27
Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00211133 2010-11-30
A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00364455 2010-04-27
Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.
Janssen-Ortho Inc., Canada
Phase 3 Completed
NCT00110955 2010-01-15
Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
Amgen
Phase 3 Completed
NCT00921635 2009-06-19
HOSTT
Tri-Service General Hospital
Phase 3 Suspended
NCT00115167 2009-05-11
A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study
Amgen
Phase 3 Completed